Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Oxford BioTherapeutics Appoints CMO, Dr. Abderrahim Fandi

Oxford BioTherapeutics
Posted on: 01 Mar 18

OXFORD, UK and SAN JOSE, CA - March [1], 2017 - Oxford BioTherapeutics (“OBT”), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate based therapies, today announced the appointment of Abderrahim (Rahim) Fandi, M.D. PhD to the newly created position of Chief Medical Officer. Dr Fandi will oversee the development of Oxford’s immune-oncology portfolio

“Rahim brings a wealth of drug development expertise to OBT which, we believe, will significantly benefit the company. This is particularly important as OBT embarks on clinical development in the United States for MEN1309, our novel ADC therapy currently undergoing clinical testing in Europe, and continues the development of our preclinical assets,” said Christian Rohlff, PhD, Chief Executive Officer of OBT.  “Rahim’s appointment represents an important step in the transition of OBT into a development focused organization.”

Prior to joining OBT, Dr Fandi was most recently at Celgene, where he led the development of several oncology compounds and participated in successful regulatory interactions, including with the FDA.  As site head of Celgene’s New Jersey site in Basking Ridge, NJ, Dr Fandi led a large multidisciplinary clinical development team before moving to Switzerland in 2014 to lead Celgene’s epigenetic program. Previously, Dr Fandi also held positions at Novartis, BMS, Astra Zeneca and Sanofi Aventis.


Dr Fandi is a docteur of Medecine and Medical Oncology at Paris University Rene Descart, Paris V. France. He gained a Clinical Pharmacoly Oncology degree from Paris VII Lariboisiere Saint-Louis and a Ph.D. degree in Experimental Pediatric at University of Turin, Italy. Following his Medical Oncology training and three years in Academia in the phase I program unit at Institut Gustave Roussy, he joined the pharmaceutical industry in 1995. He has contributed to over 100 peer-reviewed publications and abstracts including first author in lead journals such as Journal of Clinical Oncology. 

“OBT’s pipeline, including OX001R, a first in class antibody targeting a novel cancer immune escape mechanism and MEN1309, a tumor targeting ADC, which potentially can reverse immune tolerance by destroying tumor associated plasmacytoid dendritic cells, represent highly innovative approaches to cancer treatment.  I look forward to working with Christian and the OBT team to advance these novel therapies,” said Dr Fandi.

About Oxford BioTherapeutics

OBT is a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate-based therapies. OBT's IO discovery process provides unique insight into the cancer - immune cell synapse, and has identified several novel IO candidates for cancer therapy.

OBT's first two clinical programs are MEN1112 (OBT357), an ADCC* targeting Bst1/CD157-expressing AML blasts & leukemic stem cells, currently in a phase I dose escalation trial for relapsed/refractory Acute Myeloid Leukemia and MEN1309 (OBT076), a DM4 ADC** targeting CD205 in triple-negative metastatic breast cancer, bladder and pancreatic cancers as well as Non-Hodgkin Lymphoma. MEN1309 (OBT076) is currently also in a EU phase I dose escalation trial.

Oxford BioTherapeutics has struck multiple development deals commercially validating its unique target selection and development capabilities, including the collaboration with Menarini, which fully funds the clinical development of two clinical programs in the EU to completion of phase II proof-of-concept, while Oxford BioTherapeutics retains North American and Japan commercial rights. Additionally, two pre-clinical stage programs are partnered with Boehringer Ingelheim.

Oxford BioTherapeutics has a strong oncology focused management team and board with significant experience in developing immuno-oncology and antibody-based therapies. The company is based in Oxford, UK, and San Jose, CA. For further information, please see

*ADCC: Antibody-dependent cell-mediated cytotoxicity , **ADC: Antibody-drug conjugates

Media Contacts:

Dr. Christian Rohlff                                                         

Oxford BioTherapeutics                                                               

+44 (0)1235 861770


Sylvie Berrebi                                                    

Citigate Dewe Rogerson                                                               

+44 (0)20 7282 1052

Editor's Details

Mike Wood

Last updated on: 01/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.